Načítá se...
The genetic landscape of programmed death ligand‐1 (PD‐L1) alterations in head and neck cancer
OBJECTIVES: Nivolumab has recently been shown in the phase III clinical trial CheckMate‐141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum‐resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune...
Uloženo v:
| Vydáno v: | Laryngoscope Investig Otolaryngol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527359/ https://ncbi.nlm.nih.gov/pubmed/28894827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/lio2.79 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|